Gautam Jha

832 total citations
32 papers, 504 citations indexed

About

Gautam Jha is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Gautam Jha has authored 32 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Gautam Jha's work include Cancer Immunotherapy and Biomarkers (9 papers), Prostate Cancer Treatment and Research (8 papers) and Bladder and Urothelial Cancer Treatments (7 papers). Gautam Jha is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Prostate Cancer Treatment and Research (8 papers) and Bladder and Urothelial Cancer Treatments (7 papers). Gautam Jha collaborates with scholars based in United States, Netherlands and Japan. Gautam Jha's co-authors include Robert J. King, Erden Banoğlu, Badrinath R. Konety, Ayman Soubra, Arkadiusz Z. Dudek, David A. Potter, Monica Milani, Carrie P. Earthman, Philipp Dahm and Jeffrey S. Miller and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Gautam Jha

29 papers receiving 498 citations

Peers

Countries citing papers authored by Gautam Jha

Since Specialization

Citations

This map shows the geographic impact of Gautam Jha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gautam Jha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gautam Jha more than expected).

Fields of papers citing papers by Gautam Jha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gautam Jha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gautam Jha. The network helps show where Gautam Jha may publish in the future.

Co-authorship network of co-authors of Gautam Jha

This figure shows the co-authorship network connecting the top 25 collaborators of Gautam Jha. A scholar is included among the top collaborators of Gautam Jha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gautam Jha. Gautam Jha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	3068O Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274 2025 ·Annals of Oncology ·(unknown), (unknown), (unknown), Michael Schenker, Begoña P. Valderrama, (unknown), A. Bamias, Thierry Lebrét, Shahrokh F. Shariat, (unknown), Mads Agerbæk, Gautam Jha, (unknown), (unknown), (unknown), Jessica Connors, Shilpa Gupta, (unknown), Dean F. Bajorin, J.A. Witjes	0
2	Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274. 2025 ·Journal of Clinical Oncology ·Matthew I. Milowsky, Matthew D. Galsky, J. Alfred Witjes, Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebrét, Shahrokh F. Shariat, Se Hoon Park, Mads Agerbæk, Gautam Jha, Frank Stenner, Dingwei Ye, (unknown), Jessica Connors, Joshua Zhang, Dean F. Bajorin	2
3	Integrated CTC- and EV-based detection of PSMA protein and efficacy of ¹⁷⁷ Lu-PSMA-617 radioligand therapy. 2025 ·Journal of Clinical Oncology ·(unknown), Megan Ludwig, Anne Eaton, (unknown), (unknown), (unknown), (unknown), Gautam Jha, Ian J. Okazaki, Charles J. Ryan, Nicholas A. Zorko, Yingchun Zhao, Zuzan Caycı, Scott M. Dehm, Jiarong Hong, Peter W. Villalta, (unknown), Justin M. Drake, Emmanuel S. Antonarakis	0
4	Clinical outcomes in patients with metastatic castrate‐resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case–control study 2023 ·The Prostate ·(unknown), (unknown), Karan Ramakrishna, (unknown), Charles J. Ryan, Nicholas A. Zorko, Gautam Jha, Emmanuel S. Antonarakis	2
5	Extended follow-up results from the CheckMate 274 trial. 2023 ·Journal of Clinical Oncology ·Matt D. Galsky, (unknown), Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebrét, Shahrokh F. Shariat, Se Hoon Park, Mads Agerbæk, Gautam Jha, Frank Stenner, Santanu Dutta, Federico Nasroulah, Joshua Zhang, (unknown), Dean F. Bajorin	13
6	Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC). 2023 ·Journal of Clinical Oncology ·Charles J. Ryan, Qing Cao, (unknown), David James VanderWeele, Alan H. Bryce, William Kevin Kelly, Gautam Jha, Pedro C. Barata, Oliver Sartor, Walter M. Stadler, (unknown), Alicia K. Morgans, Emmanuel S. Antonarakis	1
7	PD10-01 DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA 2022 ·The Journal of Urology ·Matthew D. Galsky, J. Alfred Witjes, Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebrét, Shahrokh F. Shariat, Se Hoon Park, Mads Agerbæk, Gautam Jha, (unknown), Sandra Collette, Keziban Ünsal-Kaçmaz, Federico Nasroulah, Joshua Zhang, Dean F. Bajorin	4
8	Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan 2020 ·Anticancer Research ·(unknown), Nandita Bose, Gautam Jha, Michele Gargano, (unknown), Keith Gorden, (unknown), (unknown), Xiaohong Qiu, Arkadiusz Z. Dudek	4
9	FDG-PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients 2018 ·Clinical Genitourinary Cancer ·Ayman Soubra, Mehmet Gençtürk, Jerry Froelich, (unknown), Shilpa Gupta, Gautam Jha, Badrinath R. Konety	36
10	The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis 2016 ·World Journal of Urology ·Ayman Soubra, (unknown), Philipp Dahm, Robert Goldfarb, (unknown), Gautam Jha, Badrinath R. Konety	56
11	Malnutrition Identified by the Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition Consensus Criteria and Other Bedside Tools Is Highly Prevalent in a Sample of Individuals Undergoing Treatment for Head and Neck Cancer 2016 ·Journal of Parenteral and Enteral Nutrition ·Urvashi Mulasi, David M. Vock, Adam J. Kuchnia, Gautam Jha, Naomi Fujioka, (unknown), Manish R. Patel, Levi Teigen, Carrie P. Earthman	43
12	Phase Ib study of pembrolizumab in combination with bevacizumab for the treatment of metastatic renal cell carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003. 2016 ·Journal of Clinical Oncology ·Arkadiusz Z. Dudek, R. Alejandro Sica, (unknown), Gautam Jha, Hui Xie, Ajjai Alva, Mark N. Stein, Eric A. Singer	23
13	Challenges of managing elderly men with prostate cancer 2014 ·Nature Reviews Clinical Oncology ·Gautam Jha, Vidhu Anand, Ayman Soubra, Badrinath R. Konety	17
14	A randomized, double-blind phase 2 study of sipuleucel-T followed by indoximod or placebo in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. 2014 ·Journal of Clinical Oncology ·Gautam Jha, Jeffrey S. Miller	4
15	Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen Vaccine for the Treatment of Stage IV Melanoma 2012 ·American Journal of Clinical Oncology ·Gautam Jha, Jeffrey S. Miller, Julie Curtsinger, Yan Zhang, (unknown), Arkadiusz Z. Dudek	9
16	Abstract 2762: Phase I study of pazopanib and ixabepilone in patients with solid tumors 2012 ·Cancer Research ·(unknown), Gautam Jha, Robin Bliss, Arkadiusz Z. Dudek	1
17	Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women 2009 ·PubMed ·Monica Milani, Gautam Jha, David A. Potter	28
18	Room Air Entrainment During β-Agonist Delivery With Heliox 2006 ·CHEST Journal ·(unknown), (unknown), (unknown), Gautam Jha, (unknown), (unknown), Baljit Walia, (unknown), (unknown), Chang Shim	4
19	Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate 2001 ·European Journal of Drug Metabolism and Pharmacokinetics ·Erden Banoğlu, Gautam Jha, Robert J. King	121
20	A case of squamous cell carcinoma in a heifer associated with persistent lactation, cystic ovaries and mucometra 1973 ·Veterinary Record ·Gautam Jha, Sukesh Narayan Sinha, (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact